Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
14 search results for:

Alogliptin/Metformin 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 28-06-2017 | Topic page

    Alogliptin_Metformin

  2. 03-04-2018 | Alogliptin | News | Article

    Support for alogliptin as add-on therapy for type 2 diabetes

    Adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin and sulfonylurea treatment may improve glycemic control in patients with type 2 diabetes and high cardiovascular risk, a post-hoc analysis of the EXAMINE trial suggests.

    Published in:
    Am J Med 2018; Advance online publication
  3. 21-09-2016 | Heart failure | Article

    Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes

    Fitchett DH, Udell JA, Inzucchi SE. Eur J Heart Fail  2017; 19: 43–53. doi: 10.1002/ejhf.633

  4. 25-10-2017 | DPP-4 inhibitors | News | Article

    Metformin may moderate DDP-4 inhibitor effect on cardiovascular outcomes

    Metformin status at the time of initial dipeptidyl peptidase 4 inhibitor use may influence the effect these agents have on cardiovascular outcomes, be it positive or negative, suggest results of a hypothesis-generating meta-analysis.

    Published in:
    Diabetes Care 2017; Advance online publication
  5. 15-06-2017 | Conference report | Article
    ADA 2017

    Day 4 highlights: Monday 12th June

    She explained that these fall into three groups: Metformin based – metformin plus dipeptidyl peptidase-4 inhibitors or sodium glucose transporter 2 inhibitors Non-metformin based – alogliptin plus pioglitazone Injectible – insulin degludec plus insulin aspart or basal insulin plus a glucagon-like peptide-1 receptor agonist.

  6. 22-05-2019 | Sulfonylureas | Editorial | Article

    The CAROLINA trial: Make or break for sulfonylureas?

    Conversely, The World Health Organization categorically supports the use of sulfonylureas in type 2 diabetes patients whose glucose is inadequately controlled with metformin.  

    Author:
    Sanjay Kalra
  7. 22-11-2017 | Cardiovascular disorders | Editorial | Article

    Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

    In the EXAMINE trial, the effect of alogliptin was assessed in patients up to 90 days post-ACS [9].

    Author:
    Sanjay Kalra
  8. 21-06-2018 | Hypoglycemia | Review | Article

    Hypoglycemia among patients with type 2 diabetes: Epidemiology, risk factors, and prevention strategies

    Silbert R et al. Curr Diab Rep 2018; 18: 53. doi: 10.1007/s11892-018-1018-0

  9. 12-06-2018 | Empagliflozin | Article

    Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: Systematic literature review and indirect comparisons

    Balijepalli C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0456-7

  10. 05-06-2018 | Cardiovascular outcomes | Review | Article

    Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

    Zhuang X et al. Cardiovasc Diabetol 2018; 17: 79. doi: 10.1186/s12933-018-0722-z

  11. 01-06-2018 | DPP-4 inhibitors | Article

    Comparative effectiveness of DPP-4 inhibitors versus sulfonylurea for the treatment of type 2 diabetes in routine clinical practice: A retrospective multicenter real-world study

    Fadini GP et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0452-y

  12. 28-04-2018 | Heart failure | Review | Article

    SGLT2 inhibition and heart failure: Current concepts

    Custodio JS et al. Heart Fail Rev 2018; 23: 409–418. doi: 10.1007/s10741-018-9703-2

  13. 02-11-2017 | Heart failure | Review | Article

    Treating disease mechanisms in patients with heart failure and diabetes mellitus

    Trang A, Aguilar D. Curr Heart Fail Rep 2017; 14: 445–453. doi: 10.1007/s11897-017-0371-7

  14. 23-10-2017 | Cardiovascular disorders | Review | Article

    Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: Recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

    Schernthaner G et al. Cardiovasc Diabetol 2017; 16: 137. doi: 10.1186/s12933-017-0622-7

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.